OTC MARKETS: KALY CAVEAT EMPTOR STATUS
Due to the longstanding presence of the KALY CE designation (in Nov. 2018), Kali has created an alternative reporting website (linked below).
Without explanation as to why the site was created, we can only assume OTC markets blocked upload of files by Kali until issues are resolved.
GOLDMAN SMALL CAP RESEARCH REPORT
8300 Douglas Ave Suite 800, Dallas, TX 75225
OTC NEWS RELEASES
AUTHORIZED: 5,000,000,000 OUTSTANDING: 1,276,240,706 RESTRICTED: 255,174,312 UNRESTRICTED: 1,021,066,394
TA Verified 06/27/19 (increase of 60M from prior week)
LINK TO FINRA'S DAILY SHORT VOLUME REPORT (USE ORF SECTION)
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology
through overlapping go-to-market strategies. In addition to developing pharmaceutical products internally and through partnerships,
KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.
|Extraction Partnership - Canada Market ||Extraction Partnership ||US Cannabis Health - Joint Venture |
|KALY - NOUV ||PURA ||KALY - PURA - NOUV |
|NOUV has a cannabis cultivation business with operations |
in the U.S. and Canada. The two companies will work together
to produce cannabis extracts utilizing KALY's patented cannabis
extraction process for the recreational marijuana market.
|PURA and KALY plan to contract licensed extraction facilities |
in Colorado and California to produce THC for PURA's THCSavor
products under KALY’s patented process and supervision.
|KALY has entered into a joint venture agreement with |
Puration and Nouveau Pharmaceuticals to combine their
respective resources for the purpose of developing
partnerships with major pharmaceutical companies.
PATENTED CANNABIS EXTRACTION PROCESS
U.S. Patent No. 9,199,960 entitled “Method and Apparatus for Processing Herbaceous Plant Materials including the Cannabis Plant”
Kali Inc announced the acquisition of NCM Biotech which is the developer and owner of a patented cannabis extraction process. NCM Biotech’s current research and ongoing
pharmaceutical developments come with the acquisition. The acquired cannabis biotechnology intellectual properties will be contained within the new Kali Cannabis Therapies
subsidiary where ongoing research and development will be conducted for the purposes of producing cannabis treatments for specific conditions.
“I don’t think any cannabis extractor has more credibility or experience than we do with our patented process and preclinical trial results,” said Frederick Ferri,
CEO of Kali-Extracts. “Hemp farmers will need CBD extraction services and can’t afford to risk their crop with an inexperienced or first-time extractor. Our
franchise process will deploy trained extractors with a patented and proven process nationwide.”
Kali-Extracts plans to begin marketing the CBD extraction franchise in February.
KALI'S NEW BUSINESS PLAN
With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali will now concentrate
on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali will also concentrate on the
development of health and wellness therapies. The cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029. The cannabis concentrates
for wellness, edibles, and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022.
Prior to the acquisition by Kali, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives. As an example, and as a preview of
an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of a cannabis therapy derived from Kali’s patented extraction process
for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali’s patented extraction process is anticipated to be published soon.
NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children;
Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.
Preclinical Research Study Results on Therapy for Respiratory Disease (COPD and Asthma)
Below is a link to research recently conducted by Professor Jeffrey Osborn, President of Biomedical Science Research Group, LLC, and Biology Professor at the University of Kentucky
Final Report for Pilot Study - NCMB-1 (aka Blue Dream)
Kali-Extracts announced launching its own line of hemp-derived CBD infused candies and vapes under the brand name Hemp4mula. The company also announced initiating production on
Hemp4mula gum with a wholesale order anticipated immediately after the completion of the hemp-derived CBD infused gum production. Kali-Extracts expects to produce hemp-derived
CBD infused mints and gummies shortly after completing production of the gum. Hemp4mula vapes are anticipated to be in production early next year.
LETTER TO SHAREHOLDERS FROM INCOMING CEO FREDERICK FERRI - NOVEMBER 27, 2018
Dear Kali Shareholders –
I’m delighted to be joining you in taking Kali in a new direction. I’ve been working for years now in developing the science behind a cannabis extraction process in addition to working on applications for the
extracts from that process. As you likely already know by now, the extraction process has been patented. However, you are likely less familiar with the research that has been conducted with various extracts
derived from the patented process. Over the coming months you will have the opportunity to learn a good deal about the research. You can expect to soon see the publication of research based on the
application of extracts from the patented process in the treatment of specific conditions and diseases. In the meantime, I encourage you to visit the new Kali website my team has built to keep shareholders
up to date on our latest developments. The website is brand new and a work in progress, so check back frequently. In particular, please take time to review the section on Kali’s new business plan in
conjunction with the recent acquisition of NCM Biotech, the company I founded: https://www.kali-extracts.com/kaliextract-biz-plan
The announcement yesterday between Puration and Generex is very exciting for Kali. Let me explain why. First, you need to know that Puration is the only licensee of what is now Kali’s patented cannabis
extraction process. Puration has licensed the patent for specific, non-pharmaceutical applications. In conjunction with their license, Puration has been very successful in developing and marketing a CBD
infused bottled water called EVERx CBD Sports Water. Second, you need to know that Puration and Kali have formed a joint venture company called US Cannabis Health for the purpose of developing and
marketing pharmaceutical applications and non-pharmaceutical wellness concentrates derived from Kali’s patented extraction process. Now understanding the relationship between Puration and Kali, know
that the announcement yesterday about the agreement between Puration and Generex was part of a larger agreement executed between Generex and US Cannabis Health. While Puration will be producing
the NuGenerex CBD HydroHealth High Alkaline Water, Kali will be developing custom CBD extracts for Puration to infuse into the NuGenerex CBD HydroHealth High Alkaline Water.
With the patented extraction process now under the Kali banner, we have already developed and tested a number of different extracts as therapies for symptoms of specific health issues. We have accordingly
already initiated the process of filing for new patents in conjunction with our research. With the Generex agreement announced yesterday, we will refine our existing research to specifically target
Generex’s purposes and correspondingly file additional patent applications on behalf of Kali, Puration, US Cannabis Health and Generex.
I anticipate that with my letter today, you now have a better understanding of why I am so excited for Kali and its shareholders about the announcement yesterday by Puration and Generex. I think the Puration
and Generex shareholders should be equally excited. I am thoroughly familiar with all of the current cannabis extraction science in the marketplace and I contend that our technology is a standout. I am
confident the NuGenerex CBD HydroHealth High Alkaline Water will be a big success. I am even more excited by what I believe this first step with Generex will lead to in regard to pharmaceutical applications
derived from Kali’s patented extract process.